Cited by 195Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

Open access

Vemuri, Prashanthi, Wiste, Heather J., Weigand, Stephen D., Knopman, David S., Shaw, Leslie M., Trojanowski, John Q., Aisen, Paul S., Weiner, Michael, Petersen, Ronald C., Jack, Clifford R., Alzheimer's Disease Neuroimaging Initiative·2010·Annals of Neurology

DOI 10.1002/ana.21953PMC PMC2886799

Open this paper in CoChat — free account Open PDF

Abstract

Objective: To study the effect of apolipoprotein E ϵ4 status on biomarkers of neurodegeneration (atrophy on magnetic resonance imaging [MRI]), neuronal injury (cerebrospinal fluid [CSF] t‐tau), and brain Aβ amyloid load (CSF Aβ 1–42) in cognitively normal subjects (CN), amnestic subjects with mild cognitive impairment (aMCI), and patients with Alzheimer disease (AD). Methods: We included all 399 subjects (109 CN, 192 aMCI, 98 AD) from the Alzheimer's Disease Neuroimaging Initiative study with baseline CSF and MRI scans. Structural Abnormality Index (STAND) scores, which reflect the degree of AD‐like anatomic features on MRI, were computed for each subject. Results: A clear ϵ4 allele dose effect was seen on CSF Aβ 1–42 levels within each clinical group. In addition, the proportion of the variability in Aβ 1–42 levels explained by APOE ϵ4 dose was significantly greater than the proportion of the variability explained by clinical diagnosis. On the other hand, the proportion of the variability in CSF t‐tau and MRI atrophy explained by clinical diagnosis was greater than the proportion of the variability explained by APOE ϵ4 dose; however, this effect was only significant for STAND scores. Interpretation: Low CSF Aβ 1–42 (surrogate for Aβ amyloid load) is more closely linked to the presence of APOE ϵ4 than to clinical status. In contrast, MRI atrophy (surrogate for neurodegeneration) is closely linked with cognitive impairment, whereas its association with APOE ϵ4 is weaker. The data in this paper support a model of AD in which CSF Aβ 1–42 is the earliest of the 3 biomarkers examined to become abnormal in both APOE carriers and noncarriers. ANN NEUROL 2010;67:308–316

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/ana.21953

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citation
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Self-citation
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268

Flagged first, then by citations

Show all 61 references

Sorted by citations

Items 101–195 of 195

Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment
Kandel, B. M., Avants, B., Gee, J. C., Arnold, S. E., Wolk, D. A., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142943 · Cited by 29
Self-citation
Cerebrospinal Fluid Amyloid Beta, Tau Levels, Apolipoprotein, and 1H-MRS Brain Metabolites in Alzheimer's Disease: A Systematic Review
Piersson, A. D., Mohamad, M., Rajab, F., & Suppiah, S. (2020) · Academic Radiology · doi:10.1016/j.acra.2020.06.006 · Cited by 28
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort
Gupta, V. B., Wilson, A. C., Burnham, S. C., Hone, E., Pedrini, S., Laws, S. M., Lim, W. L. F., Rembach, A., Rainey‐Smith, S. R., Ames, D. J., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0105-6 · Cited by 26
Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum
Knopman, D. S., Jack, C. R., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.003 · Cited by 27
Self-citation
Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?
Sutherland, G. T., Siebert, G. A., Kril, J. J., & Mellick, G. D. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110026 · Cited by 26
The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals
Ingala, S., Mazzai, L., Sudre, C. H., Salvadó, G., Brugulat-Serrat, A., Wottschel, V., Falcon, C., Operto, G., Tijms, B., Gispert, J. D., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.015 · Cited by 25
Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition
Ramanan, V. K., Wang, X., Przybelski, S. A., Raghavan, S., Heckman, M. G., Batzler, A. J., Kosel, M., Hohman, T. J., Knopman, D. S., Graff‐Radford, J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa159 · Cited by 23
Self-citation
Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment
Kang, S. H., Cheon, B. K., Kim, J., Jang, H., Kim, H. J., Park, K. W., Noh, Y., Lee, J. S., Ye, B. S., Na, D. L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201092 · Cited by 26
Effect of apolipoprotein E polymorphism on cognition and brain in the Cambridge Centre for Ageing and Neuroscience cohort
Henson, R. N., Suri, S., Knights, E., Rowe, J. B., Kievit, R., Lyall, D. M., Chan, D., Eising, E., & Fisher, S. E. (2020) · Brain and Neuroscience Advances · doi:10.1177/2398212820961704 · Cited by 26
Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 25
iPSC-derived blood-brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta
Ding, Y., Palecek, S. P., & Shusta, E. V. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00580-2 · Cited by 22
Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50
Aboud, O., Parcon, P. A., DeWall, K. M., Liu, L., Mrak, R. E., & Griffin, W. S. T. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00103 · Cited by 23
Conversion from MCI to AD in patients with the APOE ε4 genotype: Prediction by plasma HCY and serum BDNF
Zheng, L., Kong, X., Cui, Y., Wei, Y., Zhang, J., & Wei, W. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.05.018 · Cited by 22
Association between apolipoprotein E gene polymorphism and mild cognitive impairment: a meta-analysis
Jiang, Y., He, T., Deng, W., & Sun, P. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143632 · Cited by 22
Disrupted Brain Structural Connectivity: Pathological Interactions Between Genetic APOE ε4 Status and Developed MCI Condition
Ma, C., Wang, J., Zhang, J., Chen, K., Li, X., Shu, N., Chen, Y., Liu, Z., & Zhang, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0224-5 · Cited by 21
Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy
Pontes‐Neto, O. M., Auriel, E., & Greenberg, S. M. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.134 · Cited by 22
The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis
Hsu, C., Hsu, T., Kao, Y., Lin, Y., Thompson, T., Carvalho, A. F., Stubbs, B., Tseng, P., Yang, F., Tsai, C., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100195 · Cited by 24
Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology
Kleinschmidt, M., Schoenfeld, R., Göttlich, C., Bittner, D., Metzner, J. E., Leplow, B., & Demuth, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-143189 · Cited by 21
High apolipoprotein E4 allele frequency in FXTAS patients
Silva, F., Rodríguez‐Revenga, L., Madrigal, I., Álvarez‐Mora, M. I., Oliva, R., & Milà, M. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.12 · Cited by 19
Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum
Solé‐Padullés, C., Lladó, A., Bartrés‐Faz, D., Fortea, J., Sánchez‐Valle, R., Bosch, B., Antonell, A., Molinuevo, J. L., & Rami, L. (2011) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.12.001 · Cited by 19
Brain tissue volumes by APOE genotype and leisure activity—the AGES-Reykjavik Study
Hafsteinsdottir, S. H., Eiríksdóttir, G., Sigurdsson, S. O., Aspelund, T., Harris, T. B., Launer, L. J., & Gudnason, V. G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.028 · Cited by 22
Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total‐Aβ42/Aβ40 ratio
Slemmon, J. R., Shapiro, A., Mercken, M. H., Streffer, J. R., Romano, G. J., Andreasen, N., Zetterberg, H., & Blennow, K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13297 · Cited by 20
Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts
Shao, K., Hu, X., Kleineidam, L., Stark, M., Altenstein, S., Amthauer, H., Boecker, H., Buchert, R., Büerger, K., Butryn, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14119 · Cited by 18
Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer’s disease biomarkers
Kulminski, A. M., Initiative, A. D. N., Jain‐Washburn, E., Loiko, E., Loika, Y., Feng, F., & Culminskaya, I. V. (2022) · Aging · doi:10.18632/aging.204384 · Cited by 17
Self-citation
FMR1 genotype interacts with parenting stress to shape health and functional abilities in older age
Seltzer, M. M., Hong, J., Greenberg, J. S., DaWalt, L. S., Baker, M. W., & Rathouz, P. J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32529 · Cited by 18
APOE ɛ4 allele and TOMM40‐APOC1 variants jointly contribute to survival to older ages
Kulminski, A. M., Jain‐Washburn, E., Philipp, I., He, L., Loika, Y., Loiko, E., Bagley, O., Ukraintseva, S. V., Yashin, A. I., Arbeev, K. G., et al. (2022) · Aging Cell · doi:10.1111/acel.13730 · Cited by 14
CSF cutoffs for MCI due to AD depend on APOEε4 carrier status
Marizzoni, M., Ferrari, C., Babiloni, C., Albani, D., Barkhof, F., Cavaliere, L., Didic, M., Forloni, G., Fusco, F., Galluzzi, S., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.019 · Cited by 15
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Aberrant interhemispheric functional connectivity within default mode network and its relationships with neurocognitive features in cognitively normal APOE ε 4 elderly carriers
Lu, H., Ma, S. L., Wong, S. W. H., Tam, C. W. C., Cheng, S., Chan, S. S. M., & LAM, L. C. W. (2017) · International Psychogeriatrics · doi:10.1017/s1041610216002477 · Cited by 14
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
The screening of Alzheimer’s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials
Dumurgier, J., Laplanche, J., Mouton‐Liger, F., Lapalus, P., Indart, S., Prévot, M., Peoc’h, K., Hugon, J., & Paquet, C. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7335-6 · Cited by 14
Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients
Knapskog, A., Eldholm, R. S., Brækhus, A., Engedal, K., & Saltvedt, I. T. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0611-4 · Cited by 13
Biomarkers for the early diagnosis of Alzheimer's disease: The challenge of XXI century
Contino, M., Cantore, M., Leopoldo, M., & Colabufo, N. (2013) · Advances in Alzheimer s Disease · doi:10.4236/aad.2013.21003 · Cited by 16
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy
Koller, E. J., Cruz, E. G. D. L., Weinrich, M. J., Williams, T., Cruz, P. E., Ryu, D. H., Golde, T. E., Sullivan, P. M., Lewis, J. M., Borchelt, D., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01859-4 · Cited by 13
The Clinical Value of Large Neuroimaging Data Sets in Alzheimer's Disease
Toga, A. W. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.008 · Cited by 12
Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype
Shvetcov, A., Thomson, S., Cho, A., Wilkins, H., Reed, J. H., Swerdlow, R. H., Brown, D. A., Initiative, T. A. D. N., & Finney, C. A. (2024) · Aging Cell · doi:10.1111/acel.14439 · Cited by 11
Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer’s disease
Ramanan, V. K., Heckman, M. G., Lesnick, T. G., Przybelski, S. A., Cahn, E. J., Kosel, M., Murray, M. E., Mielke, M. M., Botha, H., Graff‐Radford, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02419-2 · Cited by 10
Self-citation
BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Decourt, B., Gonzales, A., Beach, T. G., Malek‐Ahmadi, M. H., Walker, A. W., Sue, L. I., Walker, D. G., & Sabbagh, M. N. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030010 · Cited by 11
Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences
Moore, E. E., Liu, D., Pechman, K. R., Acosta, L. M. Y., Bell, S. P., Davis, L. T., Blennow, K., Zetterberg, H., Landman, B. A., Schrag, M., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00139 · Cited by 11
Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer’s patients in a human blood brain barrier model
Vérité, J., Page, G., Paccalin, M., Julian, A., & Janet, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201232 · Cited by 10
Comprehensive review of task-based neuroimaging studies of cognitive deficits in Alzheimer’s disease using electrophysiological methods
Casagrande, C. C., Rempe, M. P., Springer, S. D., & Wilson, T. W. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101950 · Cited by 9
Genome-wide association study of brain tau deposition as measured by 18F-flortaucipir positron emission tomography imaging
Guo, Y., Yang, Y., Zhang, Y.-R., Huang, Y., Chen, K., Chen, S.-D., Dong, P. Q., & Yu, J.-T. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.09.002 · Cited by 9
Targeted Recruitment Using Cerebrospinal Fluid Biomarkers: Implications for Alzheimer's Disease Therapeutic Trials
Barnes, J., Initiative, A. D. N., Bartlett, J. W., Fox, N. C., & Schott, J. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121936 · Cited by 9
Self-citation
Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population
Argilés, J. A. M., Gasparini-Berenguer, R., Gutiérrez-Agulló, M., Muñoz-Ruiz, C., Sánchez-Payá, J., & Leiva-Santana, C. (2016) · BioMed Research International · doi:10.1155/2016/1390620 · Cited by 9
Fluid Biomarkers and APOE Status of Early Onset Alzheimer’s Disease Variants: A Systematic Review and Meta-Analysis
Kaur, G., Poljak, A., Braidy, N., Crawford, J. D., Lo, J., & Sachdev, P. S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200052 · Cited by 10
Cerebrospinal fluid biomarkers for Alzheimer’s disease: the role of apolipoprotein E genotype, age, and sex
Mehrabian, S., Alexopoulos, P., Ortner, M., Traykov, L. D., Grimmer, T., Kurz, A., Förstl, H., Bickel, H., & Diehl‐Schmid, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s95018 · Cited by 7
A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer’s Disease
Hashimoto, M., Yamazaki, A., Ohno, A., Kimura, T., Winblad, B. G., & Tjernberg, L. O. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190700 · Cited by 7
Beyond diagnosis: What biomarkers are teaching us about the “bio”logy of Alzheimer disease
Rabinovici, G. D., & Roberson, E. D. (2010) · Annals of Neurology · doi:10.1002/ana.22020 · Cited by 7
APOE Is Associated With Serum Tau Following Uncomplicated Mild Traumatic Brain Injury
Lippa, S. M., Lange, R. T., Dalgard, C. L., Soltis, A. R., Guedes, V. A., Brickell, T. A., French, L. M., & Gill, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.816625 · Cited by 7
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort
Mao, C., Sha, L., Li, J., Huang, X., Chu, S., Lei, D., Wang, J., Dong, L., Liu, C., Xu, Q., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210344 · Cited by 6
Investigation of the Correlation between Seoul Neuropsychological Screening Battery Scores and the Gray Matter Volume after Correction of Covariates of the Age, Gender, and Genotypes in Patients with AD and MCI
Lee, S., Yoon, S., Kim, M.-J., Rhee, H. Y., Ryu, C., & Jahng, G. (2013) · Journal of the Korean Society of Magnetic Resonance in Medicine · doi:10.13104/jksmrm.2013.17.4.294 · Cited by 6
The Role of Amyloid-β, tau, andApolipoprotein Eε4 in Alzheimer Disease: How Is the Team Playing?
Filippi, M., Canu, E., & Agosta, F. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3295 · Cited by 5
Post‐Translational Modifications Distinguish Amyloid‐β Isoforms in Cerebral Amyloid Angiopathy and Alzheimer's Disease
Koutarapu, S., Roberts, K. F., Coyle, R. A., Mehla, J., Sato, C., Zipfel, G. J., Bateman, R. J., Schwetye, K. E., & Mukherjee, S. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70335 · Cited by 4
Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
Xing, F., Meng, T., Therriault, J., Luo, J., Zhang, H., & Initiative, A. D. N. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2002027 · Cited by 4
Self-citation
No effect of apolipoprotein E polymorphism on MRI brain activity during movie watching
Raykov, P., Daly, J., Fisher, S. E., Eising, E., Geerligs, L., & Bird, C. M. (2025) · Brain and Neuroscience Advances · doi:10.1177/23982128251314577 · Cited by 4
Single Nucleotide Polymorphisms in Alzheimer’s Disease Risk Genes Are Associated with Intrinsic Connectivity in Middle Age
Blujus, J. K., Korthauer, L. E., Awe, E., Frahmand, M., & Driscoll, I. F. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200444 · Cited by 4
The apolipoprotein gene: a modulating role on brain volume and cognitive function in carriers of the fragile X premutation
Jiraanont, P., Wang, J. Y., Durbin-Johnson, B., Hwang, Y. H., Hessl, D. R., Rivera, S. M., Hagerman, R. J., & Tassone, F. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107292 · Cited by 3
Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer’s Disease Biomarkers
Kang, S. H., Cho, H., Shin, J., Kim, H., Noh, Y., Kim, E., Lyoo, C. H., Jang, H., Kim, H. J., Koh, S., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210392 · Cited by 4
alzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Self-citation
Update on Dementia. Pathophysiology, Diagnosis, and Treatment. DSM-IV versus DSM-V
Nina-Estrella, R. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53126-7_34 · Cited by 3
Genetic risk factor APOEε4 associates with plasma amyloid beta in amnestic mild cognitive impairment and alzheimer’s disease
Situmeang, R., Wahjoepramono, E. J., Kaelan, C., Purba, J. S., Suhadi, B., As’ád, S., Aliah, A., Patellongi, I. J., & Wahid, S. (2016) · Medical Journal of Indonesia · doi:10.13181/mji.v25i1.1255 · Cited by 2
APOE ε4-associated hippocampal atrophy trajectories across the Alzheimer's disease continuum: a systematic review, meta-analysis, and longitudinal validation
Cai, M., Lei, H., Zhang, Y., Zou, J., Cao, W., Wang, Y., Wei, K., & Initiative, T. A. D. N. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1847611 · Cited by 2
Candidate biomarkers and CSF profiles for alzheimer’s disease and CADASIL
Bowirrat, A., Bisharat, B., William, N., Muhamad, O., & Yassin, M. (2015) · Journal of Alzheimer’s Disease & Parkinsonism · Cited by 2
Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function
Kim, H., Tian, Y., Jung, S. M., Park, S., Rhee, H. Y., Ryu, C., & Jahng, G. (2024) · Brain and Behavior · doi:10.1002/brb3.3381 · Cited by 2
Advances in Nanotechnology for Targeted Drug Delivery in Alzheimer's Disease
Maheshwari, S., Kumar, P., Dwivedi, V., Mishra, A., Singh, V. K., & Singh, A. V. (2025) · Current Aging Science · doi:10.2174/0118746098359258250727103551 · Cited by 2
Biomarkers for Alzheimer’s Disease: Imagination or Reality-View and Review!
Yassin, M., Armaly, Z., Bisharat, B., & Bowirrat, A. (2013) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2013.35040 · Cited by 2
Faculty Opinions recommendation of Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Perani, D. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.8343973.8791070 · Cited by 2
Association of modified dementia risk score with cerebrospinal fluid biomarkers and cognition in adults without dementia
Li, Q., Fu, Y., Cui, X.-J., Wang, Z.-T., Tan, L., & Initiative, A. D. N. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1339163 · Cited by 1
Self-citation
Cerebral perfusion alterations in healthy young adults due to two genetic risk factors of Alzheimer’s disease: APOE and MAPT
Bennett, S. K., Zeng, J., Dounavi, M., Majid, A., Baig, S. S., Marco, M. D., Ritchie, C. W., O'Brien, J. T., & Su, L. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241310731 · Cited by 1
REVISIÓN SOBRE LA RELACIÓN DEL GENOTIPO PARA APOE4 Y EL DESARROLLO DE DEMENCIA TIPO ALZHEIMER
Román, N., & Boza-Calvo, C. (2011) · Revista Clínica Escuela de Medicina UCR-HSJD · doi:10.15517/rc_ucr-hsjd.v2i5.6516 · Cited by 1
GENETIC DISORDER ALZHEIMER
Rani, P., Singh, K., Arjuna, A., & Devi, S. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i12.18684 · Cited by 1
Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging
Kwon, O. D. (2016) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2016.15.3.61 · Cited by 1
Ancestralidade da população de São Paulo e correlação com alterações neuropatológicas no idoso
Schlesinger, D. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2010.tde-17122010-142628 · Cited by 1
Depression in Alzheimer's disease : biomarkers and treatment
Enache, D. (2015) · Figshare · Cited by 1
Étude de l’interaction entre stress chronique et polymorphisme de l’apolipoprotéine E dans les processus émotionnels et cognitifs chez la souris : implications dans la maladie d’Alzheimer?
Koutseff, A. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Alzheimer’s Disease Genomics and Clinical Applications
Lee, T.-S. W., & Sian, M. (2011) · InTech eBooks · doi:10.5772/18773
Enfermedad de Alzheimer de inicio presenil esporádica: Caracterización clínico-biológica y diagnóstico precoz
Balasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Vasoactive Neuropeptides in Autoimmune Diseases
Brenu, E. W., Tajouri, L., Staines, D., & Marshall-Gradisnik, S. M. (2011) · InTech eBooks · doi:10.5772/20940
TEMA 6-2012: REVISIÓN SOBRE LA RELACIÓN DEL GENOTIPO PARA APOE4 Y EL DESARROLLO DE DEMENCIA TIPO ALZHEIMER
Román, N., & Boza-Calvo, C. (2012)
“Personal Training”
Tsolaki, A. (2015) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-4666-8234-4.ch002
Aging and Alzheimer's Disease
Sindi, S., Rosenberg, A., Juster, R., & LUPIEN, S. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00082-1 · Cited by 1
Alzheimer’s Dementia Screening in Primary Care: Quality Improvement Project to Identify Those at Risk
Drake, K. (2024) · Scholarworks (University of Massachusetts Amherst) · doi:10.7275/12097013
Multimodal Imaging for Enhanced Diagnosis and for Assessing Progression of Alzheimer’s Disease
Li, C. (2018) · doi:10.25148/etd.fidc006548
Assessing Cognition In A Mouse Model Of Alzheimer’s Disease
Mels, J. (2018) · Scholarship@Western (Western University)
Clinical Validation of Neuronal Pentraxin Receptor as a Candidate Biomarker for Alzheimer’s Disease
Lim, B. (2020) · TSpace (University of Toronto)
Комплексный метод анализа геометрической точности цилиндров в процессе сборки судовых малоразмерных дизелей
Яхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES
Faculty Opinions recommendation of Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
Chan, D. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.4706956.4590054
Cognition
Young, R. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc242.pub2
Etude multimodale de la maladie d'Alzheimer : forme sporadique prodromale, formes génétiques, et altération du traitement visuel
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Lost memory: what's new in the science of Alzheimer's disease and how it relates to neuroplasticity, biochemistry, biophysics and genetics
Peixoto, H., Rodrigues, R., & Nunes, S. (2023) · Journal of Student Research · doi:10.47611/jsr.v12i1.1864
Dendrimers: Advancing Therapeutic Strategies for Dementia
Singh, A., Maheshwari, S., Ansari, V. A., Verma, A., Mahmood, T., Akhtar, J., Ahsan, F., Vishwakarma, V. K., & Wasim, R. (2025) · Current Aging Science · doi:10.2174/0118746098343913250818112618 · Cited by 1
APOE genotype and astrocyte activity collectively influence AD biomarkers and Aβ burden
Chen, W., Su, F., Kong, H., Wang, Y., Yi, C., Zheng, Y., Fang, Y., Shi, X. D., Lin, Y., Zhou, J., et al. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150283
Cholinergic Differentiation of Human iPSCs Reveals Early APOE4-Driven Dysregulation of Neuronal Markers, Synaptogenesis and Inflammatory Responses
Czaniera, N. J., Schulten, W., Nowak, K., Pschik, D., Joneleit, J., Kaltschmidt, B., & Kaltschmidt, C. (2026) · Cells · doi:10.3390/cells15121057
Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis
Holst, M. A. M., Valiente, A. M. S., & Becerra, C. A. G. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09430-5

Authors: Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., & Initiative, A. D. N.
Affiliations: Mayo Clinic (US)
University of Pennsylvania (US)
University of California San Diego (US)
San Francisco VA Medical Center (US)
Alzheimer’s Disease Neuroimaging Initiative (US)
Corresponding author: Jack, Clifford R.
ORCID: Vemuri, Prashanthi
Wiste, Heather J.
Weigand, Stephen D.
Knopman, David S.
Shaw, Leslie M.
Trojanowski, John Q.
Weiner, Michael
Petersen, Ronald C.
Jack, Clifford R.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2010-03
Volume: 67
Issue: 3
Pages: 308-316
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.21953
PMC: PMC2886799
OpenAlex: W1484611135
Cited by: 195
References: 61
Citations by year: 2026: 5 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 5 · 2018: 8 · 2017: 12 · 2016: 12 · 2015: 21 · 2014: 8 · 2013: 25 · 2012: 13
FWCI: 10.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5u01ag024904-10)
National Institute on Aging (U01-AG-024904, R01AG011378, AG-11378, U19AG010483, R37AG011378)
National Center for Research Resources (RR018898, C06RR018898)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords: APOE ε4, Alzheimer's disease, amyloid-beta 42, cerebrospinal fluid biomarkers, tau protein, neurodegeneration, brain atrophy, mild cognitive impairment, amyloid load, neuronal injury
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Atrophy, Brain, DNA Mutational Analysis, Female, Genetic Markers, Genetic Testing, Genotype, Humans, Magnetic Resonance Imaging, Male, Peptide Fragments, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Apolipoprotein E4, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks